RaQualia Pharma Inc. (4579.T)
JPY 418.0
(0.24%)
JPY 418.0
(0.24%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.93 Billion JPY | 10.75% |
| 2022 | 6.25 Billion JPY | 19.55% |
| 2021 | 5.23 Billion JPY | 23.12% |
| 2020 | 4.25 Billion JPY | -12.1% |
| 2019 | 4.83 Billion JPY | 19.35% |
| 2018 | 4.05 Billion JPY | -19.98% |
| 2017 | 5.06 Billion JPY | 26.0% |
| 2016 | 4.01 Billion JPY | -15.42% |
| 2015 | 4.75 Billion JPY | -8.9% |
| 2014 | 5.21 Billion JPY | -21.53% |
| 2013 | 6.64 Billion JPY | 20.85% |
| 2012 | 5.5 Billion JPY | -34.35% |
| 2011 | 8.37 Billion JPY | 87.84% |
| 2010 | 4.46 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 10.68 Billion JPY | 54.25% |
| 2024 Q2 | 10.12 Billion JPY | -5.28% |
| 2023 Q2 | 7.2 Billion JPY | 3.55% |
| 2023 FY | 6.93 Billion JPY | 10.75% |
| 2023 Q4 | 6.93 Billion JPY | -0.54% |
| 2023 Q3 | 6.96 Billion JPY | -3.28% |
| 2023 Q1 | 6.95 Billion JPY | 11.18% |
| 2022 Q1 | 5.18 Billion JPY | -0.88% |
| 2022 Q2 | 5.93 Billion JPY | 14.43% |
| 2022 Q4 | 6.25 Billion JPY | 6.97% |
| 2022 FY | 6.25 Billion JPY | 19.55% |
| 2022 Q3 | 5.84 Billion JPY | -1.46% |
| 2021 FY | 5.23 Billion JPY | 23.12% |
| 2021 Q1 | 4.62 Billion JPY | 8.87% |
| 2021 Q2 | 4.76 Billion JPY | 3.03% |
| 2021 Q3 | 4.5 Billion JPY | -5.57% |
| 2021 Q4 | 5.23 Billion JPY | 16.24% |
| 2020 Q4 | 4.25 Billion JPY | 2.93% |
| 2020 Q2 | 4.36 Billion JPY | -2.34% |
| 2020 FY | 4.25 Billion JPY | -12.1% |
| 2020 Q1 | 4.46 Billion JPY | -7.6% |
| 2020 Q3 | 4.13 Billion JPY | -5.36% |
| 2019 Q1 | 4.02 Billion JPY | -0.66% |
| 2019 Q2 | 4.09 Billion JPY | 1.74% |
| 2019 Q3 | 3.89 Billion JPY | -4.86% |
| 2019 Q4 | 4.83 Billion JPY | 24.12% |
| 2019 FY | 4.83 Billion JPY | 19.35% |
| 2018 Q3 | 4.45 Billion JPY | -3.37% |
| 2018 Q2 | 4.6 Billion JPY | -3.7% |
| 2018 Q4 | 4.05 Billion JPY | -9.03% |
| 2018 FY | 4.05 Billion JPY | -19.98% |
| 2018 Q1 | 4.78 Billion JPY | -5.48% |
| 2017 Q2 | 3.82 Billion JPY | -7.5% |
| 2017 FY | 5.06 Billion JPY | 26.0% |
| 2017 Q4 | 5.06 Billion JPY | 37.9% |
| 2017 Q3 | 3.67 Billion JPY | -4.11% |
| 2017 Q1 | 4.14 Billion JPY | 3.02% |
| 2016 FY | 4.01 Billion JPY | -15.42% |
| 2016 Q1 | 4.82 Billion JPY | 1.56% |
| 2016 Q2 | 4.58 Billion JPY | -5.07% |
| 2016 Q3 | 4.08 Billion JPY | -10.83% |
| 2016 Q4 | 4.01 Billion JPY | -1.61% |
| 2015 FY | 4.75 Billion JPY | -8.9% |
| 2015 Q1 | 4.71 Billion JPY | -9.57% |
| 2015 Q2 | 4.18 Billion JPY | -11.36% |
| 2015 Q4 | 4.75 Billion JPY | 12.12% |
| 2015 Q3 | 4.23 Billion JPY | 1.37% |
| 2014 FY | 5.21 Billion JPY | -21.53% |
| 2014 Q3 | 5.74 Billion JPY | -3.44% |
| 2014 Q4 | 5.21 Billion JPY | -9.22% |
| 2014 Q2 | 5.95 Billion JPY | -8.09% |
| 2014 Q1 | 6.47 Billion JPY | -2.61% |
| 2013 Q3 | 6.59 Billion JPY | 23.32% |
| 2013 Q1 | 4.99 Billion JPY | -9.2% |
| 2013 FY | 6.64 Billion JPY | 20.85% |
| 2013 Q2 | 5.34 Billion JPY | 7.1% |
| 2013 Q4 | 6.64 Billion JPY | 0.77% |
| 2012 Q4 | 5.5 Billion JPY | -10.4% |
| 2012 Q1 | 7.78 Billion JPY | -7.13% |
| 2012 Q3 | 6.13 Billion JPY | -9.79% |
| 2012 Q2 | 6.8 Billion JPY | -12.54% |
| 2012 FY | 5.5 Billion JPY | -34.35% |
| 2011 Q4 | 8.37 Billion JPY | -11.64% |
| 2011 Q3 | 9.48 Billion JPY | 147.34% |
| 2011 Q2 | 3.83 Billion JPY | 0.0% |
| 2011 FY | 8.37 Billion JPY | 87.84% |
| 2010 FY | 4.46 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | -5.174% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -472.076% |
| GNI Group Ltd. | 62.39 Billion JPY | 88.893% |
| Linical Co., Ltd. | 18.53 Billion JPY | 62.62% |
| Trans Genic Inc. | 9.81 Billion JPY | 29.362% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -23.005% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 0.228% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | -19.152% |
| AnGes, Inc. | 28.89 Billion JPY | 76.014% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -699.086% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 95.591% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -328.17% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -36.657% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -59.321% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -184.862% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -192.001% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -295.687% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -36.274% |
| PeptiDream Inc. | 67.12 Billion JPY | 89.676% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -239.62% |
| Ribomic Inc. | 3.54 Billion JPY | -95.37% |
| SanBio Company Limited | 5.04 Billion JPY | -37.307% |
| Healios K.K. | 15.15 Billion JPY | 54.271% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -463.319% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -129.784% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -370.118% |
| StemRIM | 9.08 Billion JPY | 23.675% |
| CellSource Co., Ltd. | 6.87 Billion JPY | -0.735% |
| FunPep Company Limited | 2.49 Billion JPY | -178.198% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -164.65% |
| Stella Pharma Corporation | 3.82 Billion JPY | -81.391% |
| TMS Co., Ltd. | 3.55 Billion JPY | -94.958% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | -19.923% |
| Cuorips Inc. | 6.18 Billion JPY | -12.054% |
| K Pharma,Inc. | 3.31 Billion JPY | -109.127% |
| Takara Bio Inc. | 123.2 Billion JPY | 94.375% |
| ReproCELL Incorporated | 9.05 Billion JPY | 23.445% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -155.229% |
| StemCell Institute Inc. | 6.54 Billion JPY | -5.918% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 0.837% |
| CellSeed Inc. | 2.46 Billion JPY | -181.059% |